Cencora, Inc. (COR) To Go Ex-Dividend on February 14th

Cencora, Inc. (NYSE:COR) declared a quarterly dividend on Wednesday, February 5th,RTT News reports. Stockholders of record on Friday, February 14th will be paid a dividend of 0.55 per share on Monday, March 3rd. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. The ex-dividend date is Friday, February 14th.

Cencora has increased its dividend by an average of 5.3% per year over the last three years and has raised its dividend annually for the last 15 consecutive years. Cencora has a dividend payout ratio of 13.2% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Cencora to earn $16.72 per share next year, which means the company should continue to be able to cover its $2.20 annual dividend with an expected future payout ratio of 13.2%.

Cencora Stock Up 0.2 %

COR opened at $246.86 on Wednesday. The firm has a 50 day moving average price of $238.86 and a 200 day moving average price of $237.03. The company has a market cap of $47.71 billion, a PE ratio of 35.11, a price-to-earnings-growth ratio of 1.49 and a beta of 0.49. Cencora has a 1 year low of $214.77 and a 1 year high of $262.26. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.53 and a current ratio of 0.92.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Sell-side analysts expect that Cencora will post 15.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

COR has been the subject of a number of recent analyst reports. Mizuho began coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target for the company. JPMorgan Chase & Co. raised their target price on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Wells Fargo & Company raised their target price on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 29th. UBS Group raised their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Evercore ISI raised their target price on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $277.90.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 50,000 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the sale, the chairman now owns 326,557 shares of the company’s stock, valued at $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 73,187 shares of company stock valued at $17,790,912 over the last three months. Company insiders own 10.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.